tradingkey.logo

Abeona Therapeutics Inc

ABEO
5.130USD
+0.230+4.69%
Cierre 02/06, 16:00ETCotizaciones retrasadas 15 min
268.81MCap. mercado
3.17P/E TTM

Abeona Therapeutics Inc

5.130
+0.230+4.69%

Más Datos de Abeona Therapeutics Inc Compañía

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).

Información de Abeona Therapeutics Inc

Símbolo de cotizaciónABEO
Nombre de la empresaAbeona Therapeutics Inc
Fecha de salida a bolsaSep 19, 1980
Director ejecutivoSeshadri (Vishwas)
Número de empleados136
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 19
Dirección6555 Carnegie Ave, 4th Floor
CiudadCLEVELAND
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal44103
Teléfono16468134701
Sitio Webhttps://abeonatherapeutics.com/
Símbolo de cotizaciónABEO
Fecha de salida a bolsaSep 19, 1980
Director ejecutivoSeshadri (Vishwas)

Ejecutivos de Abeona Therapeutics Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Vishwas (Vish) Seshadri, Ph.D.
Dr. Vishwas (Vish) Seshadri, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.46M
+295590.00%
Mr. Michael Amoroso
Mr. Michael Amoroso
Chairman of the Board
Chairman of the Board
217.78K
+37313.00%
Dr. Leila Alland, M.D.
Dr. Leila Alland, M.D.
Independent Director
Independent Director
173.61K
-18065.00%
Mr. Donald A. Wuchterl
Mr. Donald A. Wuchterl
Independent Director
Independent Director
167.94K
-14814.00%
Ms. Christine Berni Silverstein
Ms. Christine Berni Silverstein
Independent Director
Independent Director
137.72K
-20070.00%
Dr. Bernhardt G. Zeiher, M.D.
Dr. Bernhardt G. Zeiher, M.D.
Independent Director
Independent Director
84.46K
+37313.00%
Mr. Mark J. Alvino
Mr. Mark J. Alvino
Independent Director
Independent Director
84.16K
-2000.00%
Ms. Faith L. Charles, J.D.
Ms. Faith L. Charles, J.D.
Independent Director
Independent Director
--
--
Dr. Brendan O Malley, J.D., Ph.D.
Dr. Brendan O Malley, J.D., Ph.D.
General Counsel
General Counsel
--
--
Mr. Joseph Vazzano, CPA
Mr. Joseph Vazzano, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Vishwas (Vish) Seshadri, Ph.D.
Dr. Vishwas (Vish) Seshadri, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.46M
+295590.00%
Mr. Michael Amoroso
Mr. Michael Amoroso
Chairman of the Board
Chairman of the Board
217.78K
+37313.00%
Dr. Leila Alland, M.D.
Dr. Leila Alland, M.D.
Independent Director
Independent Director
173.61K
-18065.00%
Mr. Donald A. Wuchterl
Mr. Donald A. Wuchterl
Independent Director
Independent Director
167.94K
-14814.00%
Ms. Christine Berni Silverstein
Ms. Christine Berni Silverstein
Independent Director
Independent Director
137.72K
-20070.00%
Dr. Bernhardt G. Zeiher, M.D.
Dr. Bernhardt G. Zeiher, M.D.
Independent Director
Independent Director
84.46K
+37313.00%

Desglose de ingresos

La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.

Estadísticas de accionistas

Actualizado: jue., 5 de feb
Actualizado: jue., 5 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Nantahala Capital Management, LLC
8.42%
Adage Capital Management, L.P.
5.62%
BlackRock Institutional Trust Company, N.A.
5.26%
The Vanguard Group, Inc.
5.09%
James Russell Revocable Trust
5.02%
Otro
70.59%
Accionistas
Accionistas
Proporción
Nantahala Capital Management, LLC
8.42%
Adage Capital Management, L.P.
5.62%
BlackRock Institutional Trust Company, N.A.
5.26%
The Vanguard Group, Inc.
5.09%
James Russell Revocable Trust
5.02%
Otro
70.59%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
26.88%
Investment Advisor
19.79%
Investment Advisor/Hedge Fund
10.80%
Individual Investor
7.20%
Corporation
5.02%
Research Firm
4.83%
Venture Capital
4.40%
Private Equity
2.69%
Bank and Trust
0.14%
Otro
18.25%

Participación institucional

Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
204
36.22M
79.02%
-9.77K
2025Q3
209
38.81M
82.28%
+643.18K
2025Q2
192
38.19M
68.92%
+5.47M
2025Q1
135
32.70M
74.05%
-3.55M
2024Q4
131
33.67M
75.84%
+1.89M
2024Q3
124
31.78M
82.54%
-3.17M
2024Q2
126
34.94M
52.06%
+14.17M
2024Q1
122
17.08M
56.78%
+1.44M
2023Q4
112
16.39M
53.86%
+3.77M
2023Q3
118
12.21M
54.85%
+1.48M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Nantahala Capital Management, LLC
4.56M
8.42%
+195.00K
+4.46%
Sep 30, 2025
Adage Capital Management, L.P.
3.05M
5.62%
-25.00K
-0.81%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.85M
5.26%
+131.82K
+4.85%
Sep 30, 2025
The Vanguard Group, Inc.
2.60M
4.8%
+95.88K
+3.82%
Sep 30, 2025
James Russell Revocable Trust
2.72M
5.02%
+2.72M
--
Sep 16, 2025
Suvretta Capital Management, LLC
2.68M
4.94%
--
--
Sep 30, 2025
Vivo Capital, LLC
1.84M
3.4%
--
--
Sep 30, 2025
Simplify Asset Management Inc
1.54M
2.84%
+6.42K
+0.42%
Sep 30, 2025
Seshadri (Vishwas)
1.16M
2.15%
-25.00K
-2.10%
Dec 29, 2025
Ver más

ETFs relacionados

Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Simplify Propel Opportunities ETF
3.97%
iShares Micro-Cap ETF
0.04%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
Vanguard US Momentum Factor ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Ver más
Simplify Propel Opportunities ETF
Proporción3.97%
iShares Micro-Cap ETF
Proporción0.04%
Proshares Ultra Russell 2000
Proporción0.01%
ProShares Hedge Replication ETF
Proporción0.01%
iShares Russell 2000 Growth ETF
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0.01%
iShares Russell 2000 ETF
Proporción0.01%
Global X Russell 2000 ETF
Proporción0.01%
Vanguard US Momentum Factor ETF
Proporción0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Fecha ex-dividendo
Tipo
Relación
Jul 01, 2022
Merger
25→1
Jul 01, 2022
Merger
25→1
Jul 01, 2022
Merger
25→1
Jul 01, 2022
Merger
25→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Jul 01, 2022
Merger
25→1
Jul 01, 2022
Merger
25→1
Jul 01, 2022
Merger
25→1
Jul 01, 2022
Merger
25→1
KeyAI